Equities

Xencor Inc

Xencor Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)25.01
  • Today's Change0.91 / 3.78%
  • Shares traded844.18k
  • 1 Year change+33.53%
  • Beta0.6618
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments594623334
Total Receivables, Net112966
Total Inventory------
Prepaid expenses182324
Other current assets, total------
Total current assets623675424
Property, plant & equipment, net1009460
Goodwill, net------
Intangibles, net191916
Long term investments21058332
Note receivable - long term--05.00
Other long term assets0.650.610.65
Total assets953846838
LIABILITIES
Accounts payable141014
Accrued expenses272319
Notes payable/short-term debt000
Current portion long-term debt/capital leases6.33----
Other current liabilities, total373037
Total current liabilities856471
Total long term debt1500
Total debt2100
Deferred income tax------
Minority interest0.34----
Other liabilities, total1845534
Total liabilities284119105
SHAREHOLDERS EQUITY
Common stock0.610.600.60
Additional paid-in capital1,1311,0721,018
Retained earnings (accumulated deficit)(464)(338)(283)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total1.29(6.95)(1.51)
Total equity669727734
Total liabilities & shareholders' equity953846838
Total common shares outstanding616059
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.